Monte Rosa Therapeutics, Inc. (GLUE)
| Market Cap | 1.52B |
| Revenue (ttm) | 123.67M |
| Net Income (ttm) | -38.63M |
| Shares Out | 80.02M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 713,387 |
| Open | 19.16 |
| Previous Close | 19.29 |
| Day's Range | 18.68 - 19.85 |
| 52-Week Range | 3.51 - 25.77 |
| Beta | 1.64 |
| Analysts | Strong Buy |
| Price Target | 32.00 (+68.33%) |
| Earnings Date | May 8, 2026 |
About GLUE
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL... [Read more]
Financial Performance
In 2025, Monte Rosa Therapeutics's revenue was $123.67 million, an increase of 63.54% compared to the previous year's $75.62 million. Losses were -$38.63 million, -46.87% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for GLUE stock is "Strong Buy." The 12-month stock price target is $32.0, which is an increase of 68.33% from the latest price.
News
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectiv...
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipat...
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment
Monte Rosa Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Molecular glue degraders are advancing clinical programs targeting undruggable proteins, with MRT-8102 showing strong CRP reduction and safety in early studies. Key catalysts include GFORCE-1 data in H2 2024, phase II trials for MRT-6160, and a signal-confirming study for MRT-2359 in AR-mutant prostate cancer.
Monte Rosa Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing a pipeline of molecular glue degraders, with strong clinical data in NEK7 and GSPT1 programs and multiple phase II trials set for 2024. Strategic partnerships and a robust financial position support expansion into new indications and second-generation molecules.
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, in...
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann...
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc . (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medi...
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medic...
Monte Rosa Therapeutics Transcript: Study Result
MRT-8102 achieved rapid, deep, and sustained reductions in hsCRP and fibrinogen in phase I, with 94% of high-risk CVD subjects reaching low-risk CRP levels and no serious safety concerns. The study will expand to explore additional doses and broader indications, with phase II planned for 2026.
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonst...
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann...
Why Is Monte Rosa Stock Trading Higher Today?
Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) shared interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metast...
Monte Rosa Therapeutics Transcript: Study Result
MRT-2359 plus enzalutamide showed robust and durable clinical activity in heavily-pretreated metastatic CRPC patients, especially those with AR mutations, achieving high PSA and disease control rates with a favorable safety profile. A signal-confirming phase II study is planned for 2026.
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, inc...
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann...
Monte Rosa Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing a robust pipeline of molecular glue degraders, with key assets in oncology, immunology, and cardiovascular disease, supported by strong clinical data and strategic partnerships. AI-driven platform innovation and a solid cash position enable aggressive development and future expansion.
Monte Rosa Therapeutics Transcript: Jefferies London Healthcare Conference 2025
The discussion highlighted advances in molecular glue degraders for undruggable targets, key Novartis collaborations, and progress in autoimmune and oncology pipelines. Multiple clinical readouts are expected, and the cash runway extends through 2028.
Monte Rosa Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
The summit highlighted progress in molecular glue degrader programs, with MRT-8102 showing strong selectivity and safety in early studies. Phase I data, including CRP endpoints, will be released next year, and four key indications are prioritized for Phase II. An oncology update for MRT-2359 in prostate cancer is expected soon.
Monte Rosa Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Molecular glue degraders enable targeting of undruggable proteins, with lead programs advancing in autoimmune and inflammatory diseases, as well as oncology. VAV1 and NEK7 programs show promising safety and efficacy, with multiple phase II studies planned and strategic partnerships supporting development.
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and at...
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option ex...
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model Data su...
Monte Rosa Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum
Key highlights include an expanded Novartis partnership, strong phase 1 safety and efficacy data for MRT-6160, and advancement of Next7 and oncology programs. Cash runway is extended into 2028, supporting aggressive pipeline development.
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa's growing preclinical immunology portfolio Monte Rosa ...